Trophic factors for Parkinson's disease: Where are we and where do we go from here?

Show simple item record

dc.contributor.author Gesine, Paul
dc.contributor.author Sullivan, Aideen M.
dc.date.accessioned 2020-02-18T14:58:02Z
dc.date.available 2020-02-18T14:58:02Z
dc.date.issued 2018-08-13
dc.identifier.citation Paul, G. and Sullivan, A. M. (2019) 'Trophic factors for Parkinson's disease: Where are we and where do we go from here?', European Journal of Neuroscience, 49(4), pp. 440-452. doi: 10.1111/ejn.14102 en
dc.identifier.volume 49 en
dc.identifier.issued 4 en
dc.identifier.startpage 440 en
dc.identifier.endpage 452 en
dc.identifier.issn 0953-816X
dc.identifier.uri http://hdl.handle.net/10468/9661
dc.identifier.doi 10.1111/ejn.14102 en
dc.description.abstract Perhaps the most important unmet clinical need in Parkinson's disease (PD) is the development of a therapy that can slow or halt disease progression. Extensive preclinical research has provided evidence for the neurorestorative properties of several growth factors, yet only a few have been evaluated in clinical studies. Attempts to achieve neuroprotection by addressing cell-autonomous mechanisms and targeting dopaminergic neurons have been disappointing. Four different trophic factors have so far entered clinical trials in PD: glial cell line-derived growth factor, its close structural and functional analog neurturin, platelet-derived growth factor and cerebral dopaminergic neurotrophic factor. This article reviews the pre-clinical evidence for the neuroprotective and neurorestorative actions of these growth factors and discusses limitations of preclinical models, which may hamper successful translation to the clinic. We summarize the previous and ongoing clinical trials using growth factors in PD and emphasize the caveats in clinical trial design that may prevent the further development and registration of potentially neuroprotective and neurorestorative treatments for individuals suffering from PD. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Wiley en
dc.relation.uri https://onlinelibrary.wiley.com/doi/abs/10.1111/ejn.14102
dc.rights © 2018 Federation of European Neuroscience Societies and John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Paul, G, Sullivan, AM. Trophic factors for Parkinson's disease: Where are we and where do we go from here?. Eur J Neurosci. 2019; 49: 440– 452, which has been published in final form at https://doi.org/10.1111/ejn.14102. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. en
dc.subject Animal models en
dc.subject CDNF en
dc.subject Clinical trial en
dc.subject GDNF en
dc.subject Neurotrophic factors en
dc.subject Neurturin en
dc.subject Parkinson's disease en
dc.subject PDGF en
dc.title Trophic factors for Parkinson's disease: Where are we and where do we go from here? en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Aideen Sullivan, Department Of Anatomy & Neuroscience, University College Cork, Cork, Ireland. +353-21-490-3000 Email: a.sullivan@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2020-02-18T14:49:01Z
dc.description.version Accepted Version en
dc.internal.rssid 503136232
dc.contributor.funder Knut och Alice Wallenbergs Stiftelse en
dc.contributor.funder Skåne County Council's Research and Development Foundation en
dc.description.status Peer reviewed en
dc.identifier.journaltitle European Journal of Neuroscience en
dc.internal.copyrightchecked Yes
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress a.sullivan@ucc.ie en


Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement